51. 全身性強皮症 Scleroderma Clinical trials / Disease details
臨床試験数 : 525 / 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04387825 (ClinicalTrials.gov) | August 13, 2015 | 10/5/2020 | Safety Of Fat Micrografts With Adipose-Derived Stromal Vascular Fraction In Hands Of Patients With Systemic Sclerosis | Lipograft Safety Enriched With Vascular Stromal Fraction Derived From Adipose Tissue, to Treatment of Digital Joint Fibrosis and Refractory Ischemic Digital Ulcers Caused by Systemic Sclerosis | Systemic Sclerosis | Drug: ADSVF application in the right hand | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | National Council of Science and Technology, Mexico | Completed | 18 Years | N/A | All | 20 | Phase 2 | Mexico |
| 2 | NCT01748084 (ClinicalTrials.gov) | April 9, 2013 | 10/12/2012 | Rituximab in Systemic Sclerosis | Evaluation of Rituximab in Systemic Sclerosis Associated Polyarthritis | Systemic Sclerosis | Drug: Rituximab;Drug: Placebo (NaCl) | Assistance Publique - Hôpitaux de Paris | NULL | Completed | 18 Years | 80 Years | All | 22 | Phase 2/Phase 3 | France |
| 3 | NCT00428883 (ClinicalTrials.gov) | January 2007 | 29/1/2007 | High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis | Rare Disease With Microvascular Involvement: High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis | Scleroderma, Diffuse | Drug: N-acetylcysteine (NAC) | Università Politecnica delle Marche | NULL | Recruiting | 18 Years | 80 Years | Both | 45 | Phase 2/Phase 3 | Italy |